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Infertility, spontaneous abortion and conception of trisomic offspring increase exponentially with age in mammals
but in women there is an apparent acceleration in the rate from about age 37. The problems mostly commonly
occur when the ovarian pool of follicles is depleted to a critical level with age but are also found in low follicular
reserve of other etiologies. Since recent clinical studies have indicated that dehydroepiandrosterone (DHEA)
supplementation may reverse the problem of oocyte quality, this review of the literature was undertaken in an
attempt to find an explanation of why this is effective?
In affected ovaries, oxygenation of follicular fluid is low, ultrastructural disturbances especially of mitochondria,
occur in granulosa cells and oocytes, and considerable disturbances of meiosis occur. There is, however, no
evidence to date that primordial follicles are compromised. In females with normal fertility, pre-antral ovarian theca
cells respond to stimulation by inhibin B to provide androgen-based support for the developing follicle. With
depletion of follicle numbers, inhibin B is reduced with consequent reduction in theca DHEA. Theca cells are the
sole ovarian site of synthesis of DHEA, which is both a precursor of androstenedione and an essential ligand for
peroxisome proliferator-activated receptor alpha (PPARα), the key promoter of genes affecting fatty acid metabolism
and fat transport and genes critical to mitochondrial function. As well as inducing a plethora of deleterious changes
in follicular cytoplasmic structure and function, the omega 9 palmitate/oleate ratio is increased by lowered activity
of PPARα. This provides conditions for increased ceramide synthesis and follicular loss through ceramide-induced
apoptosis is accelerated.
In humans critical theca DHEA synthesis occurs at about 70 days prior to ovulation thus effective supplementation
needs to be undertaken about four months prior to intended conception; timing which is also suggested by
successful interventions to date. In humans and primates that undergo adrenarche, the adrenal zona reticularis (ZR)
is the major site of DHEA production, however this is also reduced with age. Concomitant loss in function of the ZR
might account for the acceleration in the rate of aging seen in humans in the late thirties’ age group.
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Maternal aging is associated with a dramatic increase in
infertility, a high risk of miscarriage and of giving birth
to live-born infants with Down’s syndrome. As women
increasingly defer child bearing, this biological problem
is becoming a growing social and health economic issue.
Reproductive aging has been extensively studied during
the last fifty years, initially most intensively by human
geneticists and more recently by scientists and clinicians
working with assisted conception. Nevertheless despite
the huge input no one explanation has fitted all the data.
Part of the problem in trying to explain a biological
phenomenon of this type is that the evidence crosses
many sub-disciplines. Today, as research techniques
become more refined and the evidence generated more
complex, silos of knowledge are generated and experts
find it difficult to cross between sub-disciplines. This
paper will attempt to coordinate the information from
several areas to find a logical model from the data that is
currently available.
The problem of reproductive aging
Initially, extensive international data showed fairly con-
sistent age-related risks of Down’s syndrome live-births
in different ethnic groups [1]: the rate was about 1/1490
at age 20–24, 1/200 at 35, 1/60 at 40 and 1/11 at 49.
The observed trisomic births, however, were soon found
to be only the tip of the iceberg. Older women have an
extremely high rate of pregnancy loss of both chromo-
somally normal and abnormal conceptions and increasedFigure 1 Graph of the frequency of spontaneous abortion by age, am
who had no interventions and were studied prospectively from the ti
PALS: Pregnancy and Lifestyle Study.rates of spontaneous abortions occur at similar ages as
the Down syndrome births (Figure 1); moreover spon-
taneously aborted conceptions that are chromosomally
abnormal are mostly trisomic [2]. Recent large studies
using assisted reproductive technology have confirmed
that aneuploidy is a leading impediment to reproduction
in older women [3].
Many cytogenetic-based hypotheses have been put
forward to explain the mechanisms underlying the
generation of maternal age trisomies and many of these
are summarised [4,5]. Various aspects of meiosis appear
to be adversely affected by the aging process but no one
mechanism explains all the data. The impression is that
there is a multiply determined deterioration of the mei-
otic process with aging. Some have proposed that this is
caused by an age-dependent system of gamete selection
where the last remaining follicles are inherently defective
but there is no mechanism outlined for such selection.
Although the disturbances of meiosis and the con-
sequent chromosomal abnormalities have attracted the
most attention of geneticists seeking to explain the
underlying mechanisms, all cytogenetic studies of age-
related pregnancy losses also showed high rates of loss
of chromosomally normal conceptions. These chromo-
somally normal embryos appeared to show the same
range of developmental abnormalities and developmen-
tal arrest as those that were chromosomally abnormal
[6,7], which suggests that the underlying problem of the
aging oocyte may be cytoplasmic rather than nuclear in
origin. There is no doubt that genetic imbalances areongst pregnancies monitored in a group of normal women
me they attempted to conceive in a study known as the
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the developmental abnormalities found in both chromo-
somally normal and abnormal abortuses could be caused
by disruptions to cell division (both meiotic and mitotic),
secondary to abnormalities of structure and function of
cytoplasmic organelles, and the consequences on cell
number, size and distribution.
Ultrastructure, cytology and gene expression of granulosa
cells and oocytes in normal and aging ovaries prior to
ovulation
The competence of granulosa cell mitochondria is critical
to follicle survival and function. Detailed studies of the
ultrastructure of resting follicles in younger, aged 27–32,
and older, aged 38–45 women showed statistically signifi-
cant age-related changes in the cytoplasmic organelles of
the granulosa cells, including changes in the density of the
mitochondrial matrix, the frequency of dilated smooth
endoplasmic reticulum and Golgi complex [8]. When
granulosa cells from peri-ovulatory follicles of younger
(aged 20–32) and older (aged 38–41) women attending an
IVF program were compared, the expression of mRNA
and protein levels from the mitochondrial genes super-
oxide dismutases Cu and Zn SOD1, Mn SOD (SOD2) and
catalase were all significantly decreased in the older
women [9]. Ultrastructural studies of the granulocytes
from the older women showed structurally defective
mitochondria and fewer lipid droplets in 63.3% of cells. By
comparison, only 8.2% of cells of the younger women
showed ultrastructural defects.
In resting follicles (oocyte size about 900 μm), oocytes
of older women show a significant increase in the
fraction of vacuoles compared with younger women and
whilst the nuclear and cytoplasmic membranes and
number of microvilli showed no apparent difference
between younger and older women, the proportion of
mitochondria showing a high density matrix was highly
significantly increased with age [8].
The possibility of mitochondrial dysfunction playing a
key role in a cytoplasmic-based cause of age-related
problems is further supported by recent studies in aging
mice oocytes that demonstrate that mitochondria are
both morphologically abnormal and are decreased in
abundance [10]. Furthermore, studies of oxidative phos-
phorylation in individual bovine oocytes showed that
aged oocytes have reduced maximum respiratory cap-
acity [11] and aging meiosis II oocytes in mice and
hamsters have lower levels of ATP [12]. These studies all
support earlier work that found that the adenosine
triphosphate (ATP) content of human oocytes is corre-
lated with developmental potential and outcome after
in vitro fertilization [13].
Some researchers have considered that cumulus cell
function may be a more major determinant than theoocyte itself of the quality of the mitochondria in the
activated oocytes. In elegant studies undertaken to
determine which cumulus genes were both induced by
the LH peak and critical to oocyte competence, mRNA
expression in cumulus cells was prospectively studied in
human oocytes that would be used for intracytoplasmic
sperm injection [14]. Gene functions that were up-
regulated in cumulus cells were identified in mature
oocytes (meiosis II compared to Germinal vesicle (GV)
stage cells) and those that were up-regulated in cumulus
cells from mature oocytes that yielded a blastocyst at
day 5/6 of in vitro culture. In all, 23 up-regulated func-
tions were identified, one of which was ‘fatty acid
biosynthesis’ and in a previous paper where they studied
the expression of six key genes, the same group specific-
ally identified that both delta-9 desaturase and delta-5
desaturase were up-regulated in top quality embryos at
day 2 [15]. Nevertheless, these same genes had lower
mean expression in the fertilized oocytes that produced
high quality embryos after 5–6 days of culture than in
those that had low grade embryos, suggesting that in the
optimum follicles, the regulation of these and other
genes are under tight control. In a somewhat similar
study, proteomics was used to study 1423 cumulus
proteins in the follicles of younger and older women
[16]. These authors found age-related differences in 7.7%
of the levels of protein expression and the majority of
the genes that differed between age-groups were
involved with metabolism, oxidative phosphorylation
and post-transcriptional mechanisms.
The results of all the ultrastructural and biochemical
studies make it clear that the structure and function of
the cytoplasmic organelles, especially the mitochondria,
of both the oocytes and the granulosa cells, which are
critical to fertilization and normal embryonic develop-
ment, are markedly compromised in the oocytes of older
women prior to ovulation. The studies do not, however,
prove that the primordial follicles, held in the dictyotene
stage of meiosis, are in any way compromised nor that
there is any complex system of follicle selection as has
been proposed in some of the previous hypotheses [4,5].
Since studies have not yet been undertaken it is possible
that the primordial follicles are already compromised
however, if they are not compromised, then there is an
age-determined and follicle reserve size effect on oocyte
development that is responsible for the disturbed
function and deleterious outcomes that affects follicles
during development from primordial follicle to about
900 μm size.
DHEA supplementation for low follicular reserve
Possible therapeutic effects from DHEA supplemen-
tation were first suggested by Casson [17]. Since then
many IVF clinics have tested regimes in which they
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ovarian reserves with DHEA. Extensive clinical work has
been undertaken by Gleicher and Barrad [18] and many
of the published results have recently been reviewed
[19]. The latter authors concluded that while several
studies show improvements in pregnancy rates, large
randomized prospective trials are still needed. Current
studies differ in the dosages of DHEA given and seem to
be rather haphazard in the duration of treatment given.
To date treatments that are most successful use inter-
ventions of about 12 weeks and this suggests that
deficiency of DHEA might exert its affects on the earli-
est stages of follicle growth, possibly at the pre-antral
stage.
One of the greatest difficulties in assessing the current
treatments is the mix of patients used. For example, one
recent study used only ‘poor responders’ [20] and
achieved no increase in clinical pregnancies. Despite
this, the study showed that after three months of daily
treatment with 75 mg DHEA, participants had increased
retrieval of mature oocytes and dramatic reduction in
follicular fluid hypoxic inducible factor 1 (HIF-1) levels.
The authors suggested that the best reproductive out-
comes from DHEA treatment in poor responders may
be due to the effect on the follicular microenvironment.
By comparison a ‘self-controlled’ study of 32 women
with various causes of infertility including age, using the
same DHEA treatment, had both increased numbers of
retrieved oocytes and increased fertilization rates [21]. It
thus seems that there are positive effects from treatment
with DHEA but that the treatment might not be appro-
priate for all patients as apart from aging, many other
different mechanisms can cause reduction of the follicu-
lar reserve.
Ovarian theca, androgens and reproductive aging
Androgens and key roles in ovarian steroidogenesis and
effects of age
Theca cells have been referred to as the forgotten cell of
the ovarian follicle [22] and yet they play a pivotal role
in providing both structural and androgen-based hor-
monal support to the developing follicles: they are the
sole ovarian site for the production of dehydroepian-
drosterone (DHEA) and androgens. To date there has
been a dearth of studies published on the earliest
theca function and aging in normal women possibly
because studies have focussed on the biochemical and
cellular events closer to the time of ovulation. It is
for this reason that the following study is described
in detail.
Female macaques are similar to women in having a
28 day menstrual cycle, a natural menopause following a
period of decline in follicle numbers and a similar hor-
monal profile. Thus Ethun [23] used the cynomolgusmacaque as a model to study theca function and the rela-
tionship between androgen synthesis and aging The rela-
tive expression of the androgenic enzymes P450c17 and
Cytb5 versus 3βHSD were measured by immunofluores-
cence and used to characterise androgen synthesis in the
different cell layers at each stage in follicle growth in each
of 26 monkeys. High expression of the 3βHSD enzyme
competes with P450c17 such that if 3βHSD is high, preg-
nenolone is converted into progesterone but in the ab-
sence of 3βHSD, P450c17 is converted into DHEA. In
each monkey, one ovary was used to determine the total
number of primordial follicles while the other was used
for immunohistological studies. The major finding with
respect to aging was that theca DHEA and other androgen
production was influenced by follicle number: immuno-
staining for androgenic enzymes in the theca interna layer
of growing follicles was reduced in all ovaries with lower
numbers of follicles. Androgenic enzymes were only
expressed in the theca cells, not the granulosa cells, and
the androgenic enzymes P450c17 and CYTB5 were first
expressed in the theca cells at the advanced secondary fol-
licle stage (≥ 150 μm) and then more intensely in the an-
tral follicles.
In the advanced secondary follicles only P450c17
and CYTB5 were expressed. In antral follicles, the
staining of each of these enzymes was increased in
intensity but 3βHSD was also expressed at a low
level. Thus DHEA is first produced in theca cells of
advanced secondary follicles. Studies using the same
enzyme localisation technique in human follicles gave
similar evidence of early synthesis of DHEA by theca
cells but staining was not observed in follicles smaller
than 200 μm [24,25]. Neither of these groups per-
formed age-related studies.
Theca DHEA has a direct role in androgen synthe-
sis and is converted in the theca cells to androstene-
dione which is in turn transported to the granulosa
cells where after binding to the androgen receptor, it
is converted into estrone and 17β estradiol [22]. Just
as importantly, however, theca DHEA stimulates the
production of peroxisome proliferator-activated recep-
tor alpha (PPARα) and in rat ovaries PPARα expres-
sion is limited to the theca and stromal cells [26].
Moreover, DHEA is a ligand for PPARα and is necessary
for gene induction by DHEA [27]. In general, PPARα plays
a key role in fatty acid metabolism and is highly expressed
in mammalian tissues such as the heart, brown adipose
tissue, kidney, intestine and the liver [28] and white adi-
pose tissue [29]. PPARα promotes fatty acid transport
across membranes, including into mitochondria, as well
as up-regulating delta-9 (also known as stearoyl CoA-
desaturase 1) and delta-6 desaturases (the key enzymes in-
volved in fatty acid desaturation and elongation in the
Omega 3,6 and 9 pathways) and genes critical to
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PPARα regulates some 240 target genes, which include
delta-6 and delta-9 desaturases and the majority, if not all,
genes involved in mitochondrial oxidative phosphorylation
[31]. Reduced expression of PPARα in the aging theca is
probably sufficient to account for the initiation of the
subsequent cytoplasmic dysfunction observed in aging
oocytes.
The effect of DHEA treatment on mitochondrial func-
tion has been demonstrated in both rat liver and brain
where it significantly stimulated many mitochondrial en-
zymes and up-regulated oxidative energy metabolism
[32], presumably through activation of PPARα. Further-
more, PPARα is upregulated in response to oxidative
stress [33] and it is likely that PPARα upregulation ac-
counts for the reduction in HIF-1 levels in DHEA
treated ‘poor responders’ [20].
Low androgens: ceramide production and acceleration of
follicle loss through apoptosis
Ceramide, a major component of the lipid bilayer of
cell membranes, can participate in cellular signalling.
In aging oocytes in Drosophila, disturbances of cer-
amide and its transport protein (CERT) were found
to contribute to disturbances of structure and func-
tion of mitochondria [34]. In mice, ceramide was
found in all the cumulus cells in old mice whereas it
was rare, present in only about 5% of the cumulus
cells of young mice. When present, ceramide is trans-
located from the cumulus cells to the oocytes through
gap junctions and in older mice, spikes in ceramide
levels, lead to apoptosis [35]. Using primary mouse
myoblast cultures, [36] have shown that dihydrocera-
mide desaturase (DESI), the enzyme that controls the
synthesis of ceramide, is dependent on palmitate.
Higher levels of cellular palmitic acid increase mRNA
encoding DESI whereas co-treatment with oleate pre-
vents the increase in ceramide.
Delta-9 desaturase, one of the key enzymes regu-
lated by PPARα, is the key enzyme involved in the
conversion of palmitic acid to oleic acid. When levels
of this enzyme are low, the levels of palmitic acid
will rise relative to oleic acid, conditions that pro-
mote the production of ceramide and hence condi-
tions that promote apoptosis and accelerated loss of
follicles.
Age and pre-antral development
The time taken by human follicles to develop from
the pre-antral follicle of about 150 μm to the mature
follicle of 1500–2000 diameter μm is about 70 days
[37]. If the earliest stages of theca development and
DHEA expression are important to the normal devel-
opment of the follicle, and these commence at aboutthe 200 μm size, then by the time oocytes reach
900 μm (the size used in the ultrastructural studies
above), they have already been exposed to an
androgen-dependent cellular environment for a con-
siderable period of time. Indeed since age-related or
follicle-depleted altered levels of androgens might be
expected to have major effects on the development
and function of the cytoplasmic organelles in the two
to three months prior to ovulation, any successful
treatments of age-related theca dysfunction would
need to occur within this period.Age-related rates –mathematical models
One outstanding feature of the trisomy data is its
age-related rates, which show a relatively gradual rate
of increase up to about age 37 and then greatly accel-
erate. The complexity of the rates has been discussed
by many authors but was first studied in some detail
by Penrose e.g. [38] and then taken up at length by
Hook e.g. [39]. Authors argued that there was either
a statistical artefact or that there was likely to be
more than one parameter determining the rate, per-
haps a maternal age independent and a maternal age
dependent component?
It was predicted [40] that oocyte aging could be
estimated from the size of the ovarian follicular store,
once that could be measured. Overall, the decline in
the size of the pool shows a remarkably consistent
relationship with female age and the point of age-
related change is essentially identical to those of age-
related changes for each of live Down syndrome
births and the rates of trisomy. With mathematical
modelling Faddy [41] describes the curve of logged
total numbers of follicles against age that corresponds
to a ‘broken stick’ bi-exponential regression. In this
model, there is an obvious acceleration of the rate of
follicle loss that starts at about age 38 whereas others
propose [42] that the apparent biphasic phenomenon
can be better explained by a ‘power model’ that pro-
poses that decay of non growing follicles (NGF) is
constantly accelerating. When tested against the
‘power’ model predictions, the following regression
values were observed: age r = − 0.80, antral follicle count
(AFC) r = 0.78, anti-Mullerian hormone (AMH) r = 0.72,
follicle stimulating hormone (FSH) r = − 0.32 and inhibin B
(r = 0.40).
The ovarian pool has also been studied in mice
[43,44]. In rodents there is also an exponential decrease
in the size of the ovarian pool with aging but unlike in
humans, there is no evidence of a ‘broken stick’
phenomenon; the rate of aging appears to occur at a
consistent rate. Moreover the rates of follicle loss appear
to differ between strains.
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It is clear that AMH is the best indicator of follicle
numbers but whilst the AMH-specific receptor type II
(AMHRII) may be expressed in the theca cells of pre-
antral and antral follicles [45], the major role of
AMH seems to be as an inhibitor of recruitment of
primordial follicles [46]. AMH is positively correlated
with follicle number so levels decline with increasing
age and decreasing follicle numbers. Follicle stimulat-
ing hormone (FSH) has long been recognised as a
marker of reproductive decline and although an im-
perfect predictor of ovarian response [47] is a reason-
able marker of the relationship between reproductive
decline and age. FSH levels are positively correlated
with age. The correlation with follicle numbers in the
model above was only – 0.32 and FSH levels may be
more related to inhibin B which plays a critical role
in mediating the age-related rise in FSH in older
women; neither activin A nor inhibin A seems to
show age-related changes [48].
The relationships of Inhibin B and A, FSH, estra-
diol and progesterone levels to aging were further
elucidated in a study that measured the four hor-
mones across the menstrual cycles in younger (less
than 35) and older women (35 and older), and in
longitudinal studies at 10 year intervals in three
women [49]. In these studies both inhibin B and A
were observed to decline with age but the decline in
inhibin B precedes that of inhibin A and more im-
portantly, the decline in inhibin B precedes the in-
crease in FSH. The reduction in inhibin B was most
dramatic when measured in the early and mid-luteal
phases.
Androstenedione, the immediate androgen product
of DHEA also shows an age-related profile, which
over the reproductive years is quite similar to the de-
cline in reproductive competence [50]. Reference
values for about twenty participants in each age
group showed mean ± SD serum androstenedione
values (nmol/l) of - ages 21–25: 5.8 ± 1.7; ages 26–30:
5.2 ± 1.4; ages 31–35: 5.3 ± 2.6; ages 36–40: 4.7 ± 2.2;
ages 41–45 (pre-menopausal): 3.4 ± 1.2 and post-
menopausal: 3.7 ± 1.3.
Androgen paracrine regulation by inhibin B and ovarian
follicle decline
Inhibin B has been shown to stimulate the synthesis
of androgens and proliferation in primary cultures of
ovarian theca cells whilst activin inhibits them [51].
Inhibin B is secreted from the granulosa cells of de-
veloping preantral follicles and small antral follicles in
intact follicles in culture but is not directly stimulated
by FSH [52]. The role of inhibin B has been reviewed
extensively and it is concluded that inhibin B hasparacrine or paracrine-like action, positively upregu-
lating androgen production by ovarian theca cells (e.g.
[53]. Furthermore, mutations in the inhibin alpha
gene INHα are significantly associated with premature
ovarian failure [54].
Inhibin B suppresses serum follicle stimulating hor-
mone (FSH) concentration [55] so high levels of FSH
always indicate low inhibin B. Although low inhibin B
is not the best predictor of follicle number, its decline
has been described as a ‘primary event in the aging
of the reproductive axis’ [56] and is one of if not the
‘earliest marker of decline in follicle number’ [49].
Moreover, since inhibin B is needed to upregulate
DHEA production in theca cells and DHEA plays a
key and direct role in theca androgen synthesis then
inhibin B almost certainly plays a major role in the
regulation of age-related change.
Relating biochemical changes to the maths
(a) The mammalian system.
The decline with age of inhibin B and the
subsequent effects on DHEA, androgen synthesis,
PPARα activation and altered regulation of
hundreds of genes is sufficient to explain both the
effects of aging on decline in quality and pregnancy
outcome and the accelerated loss of follicle number
that is observed in mammals and is most well
defined in rodent models. It does not, however,
explain the accelerated decline seen in humans in
the late-thirties age group. This requires an extra
factor that is absent in rodents and other mammals
and indeed in many primates.
(b) Humans and close primate relatives- an additive
role of the adrenal cortex zona reticularis?
In humans and those primates that undergo
adrenarche, the adrenal cortex zona reticularis (ZR)
is the key site of synthesis of DHEA and its
sulphate DHEAS. In humans, adrenal synthesis is
high during fetal development then falls rapidly
after birth. At about age five to six, the levels start
to rise again (the stage known as adrenarche) until
levels reach a peak at about age 20 [57]. From age
20 onwards in men and women, the synthesis of both
dehydroepiandrosterone (DHEA) and its sulphate
ester DHEAS decline, although levels in males are
almost double those in females [58]. In aging of the
adrenal cortex, the decline in the biosynthesis of
DHEA and DHEAS are the most striking changes
and the simplest, but not yet proven hypothesis, is
that it results from a decline in the number of
functional zona reticularis (ZR) cells, which secrete it
[59]. The age-dependent reduction in the physical
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the size of the adrenal cortex is controlled is only
partly understood, it is known to involve feedback
via the hypothalamus and pituitary” [59].
Low serum inhibin B, associated with low follicle
number may also be a determinant of reduced
adrenal ZR function since inhibin B and activin are
expressed in the adrenal cortex ZR and play major
signalling roles in the ZR [60]. Indeed the alpha
sub-unit of inhibin is only expressed in the ZR cells
of the adrenal cortex [61]. Whether ACTH is
independently involved or whether the age-related
physical loss of adrenal ZR cells is the critical factor
remains to be determined. However this
additional site of loss of production of DHEA
could easily account for the sudden acceleration
of the age-related deterioration after about
age 37. That the ‘broken stick’ graph has thus
far only been reported in humans and not in
other mammalian models that lack adrenal
synthesis of DHEA lends strong weight to
this model.One important limitation to this model is the
current lack of information in humans concerning the
relative age-related rates of synthesis of DHEA by the
ovary and the adrenal glands and whether there is
any specific requirement for synthesis within the
theca cells. Serum steroid levels from normal females
and one female with bilateral adrenalectomy indicatedure 2 The model (left and above dotted line) shows the response
HEA and PPARα in follicles from about 200 μm. It is proposed that
cle number and the loss of oocyte quality that ultimately leads to error
plasmic organelles, especially mitochondria, are largely responsible for
tabolism and transport and mitochondrial function that are directly cau
nges also lead to increased production of ceramide, apoptosis and hen
t of the dotted line indicates that in humans and those primates where
ted loss of ZR cells accelerates the rate of aging in the late thirties agethat the ovaries synthesise about 20% of DHEA and
that this is maximal at mid-cycle [62]. Similar esti-
mates of the ovarian contribution to DHEA were
achieved when DHEA levels were measured before
and after dexamethasone suppression of adrenal func-
tion [63]. Although the postmenopausal ovary is well
known to actively secrete DHEA and androgens [64],
to date there is no study that shows the relative con-
tributions that occur from the two organs at different
ages in normal women.
The question of whether DHEAS could be used effect-
ively as a pre-hormone for ovarian steroidogenesis was
studied using radioactively labelled DHEAS and T. The
results demonstrated that plasma DHEAS served as a
pre-hormone for 48% of follicular fluid testosterone
however, the fractions of androstenedione, estrone and
estradiol that were labelled were minimal, each only
about 4% [65]. These data suggest that there may indeed
be a specific requirement for synthesis of DHEA within
the theca cells.
Conclusions
From the collective studies summarised in this review, it
is concluded that mammalian female reproductive aging
is caused by the gradual depletion of follicles which,
through actions of lowered levels of inhibin B acting on
the theca cells at the advanced secondary follicle stage,
results in lowered levels of ovarian synthesis of DHEA.
This in turn leads to reduction in the activity of many
key metabolic systems. Both androgens and estrogensof the pre-antral theca to inhibin B, which results in production
reduced levels of PPARα primarily account for both the decline in
s of cell division and arrested development. The defects that occur in
decline in follicle quality. These can be attributed to key changes in fat
sed by dysfunction of PPARα secondary to low DHEA. These same
ce accelerated decline in the size of the follicle pool. The area to the
the adrenal ZR produces an alternative source of DHEA, that age
group.
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tion of PPARα is paramount because of its role in the
activation of key enzymes affecting fatty acid synthesis
and mitochondrial oxidative phosphorylation. Its effect
on the down-regulation of the fatty acid enzyme delta-9
desaturase accounts for increased production of cera-
mide with aging and consequent increased rates of
atresia. The model, which has been developed from the
findings is depicted in Figure 2. It accounts for both the
loss of follicles, and correlated decrease in quality that
occur at a consistent exponential rate with aging in most
mammals. Consequently, as well as increasing steroid
levels, treatment with DHEA both reduces ovarian
oxidative stress and rates of atresia.
In humans and some primates that undergo adre-
narche, DHEA is also produced by the specialised area
of the adrenal cortex known as the zona reticularus
(ZR). The number of ZR cells declines markedly with
age and the synthesis of adrenal DHEA is greatly affec-
ted by aging. Whether the lowered levels of inhibin B
play a role in the age-related reduction of synthesis of
adrenal DHEA or whether this is entirely independent
and caused only by the reduction of ZR cells needs to be
determined. As outlined in Figure 2, it is proposed that
the decline in ZR function in humans with aging
accounts for the accelerated decline in the quality of
reproduction and increased rate of follicle loss that
occurs in women after about age 37.
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